Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT06337708 per Attività fisica, Esercizio, Malattie cardiache, Diabete mellito, Inattività fisica è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca
Università statale dell'ArizonaSmart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT06337708 è uno studio interventistico di Fase II volto a esaminare la prevenzione per Attività fisica, Esercizio, Malattie cardiache, Diabete mellito, Inattività fisica, attualmente in arruolamento. Avviato il 8 aprile 2024, prevede di arruolare 240 partecipanti. Sotto la guida di l'Università statale dell'Arizona, dovrebbe concludersi entro il 31 marzo 2028. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 16 maggio 2025.
Sommario breve
The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.
Descrizione dettagliata
This study addresses major public health concerns among African American women: physical inactivity and cardiometabolic disease risk.
African American women experience a high burden of cardiometabolic diseases, including heart disease, obesity, and type 2 diabetes. Regular aerobic physical activity is an established behavior to prevent and treat these conditions. Yet, the many African American women are insufficiently active, with only 27-40% meeting national aerobic physical activity guidelines.
This study will test the efficacy of Smart Walk, a culturally tailored, theory-based smartphone-delivered intervention designed to increase physical activity and improve cardiometabolic disease risk factors among African American women. In a 12-month trial, participants will be randomly assigned to either the Smart Walk intervention or a Fitbit-only comparison arm for an active 4-month intervention period, followed by an 8-month minimal contact follow-up period.
Specific Aims:
- Test the effects of Smart Walk to increase physical activity and promote adherence to national aerobic physical activity guidelines; compared to Fitbit-only comparison group.
- Test the effects of Smart Walk to improve cardiometabolic risk factors; compared to Fitbit-only comparison group.
- Compare cost and cost effectiveness of the two intervention groups from a societal perspective.
- Examine if protocol adherence predicts outcomes and potential mediation and moderation of intervention effects on physical activity and cardiometabolic outcomes.
Titolo ufficiale
Smart Walk: An Efficacy Trial of a Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
Condizioni
Attività fisicaEsercizioMalattie cardiacheDiabete mellitoInattività fisicaAltri ID dello studio
- STUDY00017286
- R01HL168170 (Sovvenzione/Contratto NIH (USA))
Numero NCT
Data di inizio (effettiva)
2024-04-08
Ultimo aggiornamento pubblicato
2025-05-16
Data di completamento (stimata)
2028-03-31
Arruolamento (previsto)
240
Tipo di studio
Interventistico
FASE
Fase II
Stato
In arruolamento
Parole chiave
mHealth
women's health
health equity
African American women
Black women
exercise
physical activity
heart disease
diabetes
women's health
health equity
African American women
Black women
exercise
physical activity
heart disease
diabetes
Scopo principale
Prevenzione
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Singolo
Bracci / Interventi
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
SperimentaleSmart Walk Participants will receive a culturally tailored smartphone-delivered physical activity intervention. | Smart Walk Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts). |
Comparatore attivoFitbit Participants will receive a Fitbit Inspire 3 activity monitor. | FitBit This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity. |
Esito primario
Esito secondario
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Change in accelerometer-measured moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months | Participants will wear wrist-worn ActiGraph GT9X Link Activity monitors the activity monitor on their non-dominant wrist during all waking hours for 7 consecutive days to provide an assessment of usual activity | Assessed at baseline, 4-months, 12-months |
Change in self-reported moderate-to-vigorous intensity physical activity from baseline to 4- and 12-months | Assessed by the 7-Day Physical Activity Recall | Assessed at baseline, 4-months, 12-months |
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Change in cardiorespiratory fitness from baseline to 4- and 12-months | A modified Balke treadmill protocol will be used to estimate maximal aerobic capacity (i.e., VO2 peak). | Assessed at baseline, 4-months, 12-months |
Change in aortic pulse wave velocity from baseline to 4- and 12-months | A measure of aortic stiffness and will be assessed using SphygmoCor XCEL system using validated methodology. | Assessed at baseline, 4-months, 12-months |
Change in body weight from baseline to 4- and 12-months. | Measured in kilograms using an electronic scale | Assessed at baseline, 4-months, 12-months |
Change in body mass index from baseline to 4- and 12-months | Calculated using the formula: weight (in kilograms) / height (in meters)squared | Assessed at baseline, 4-months, 12-months |
Change in waste circumference from baseline to 4- and 12-months | Measured in centimeters | Assessed at baseline, 4-months, 12-months |
Change in blood pressure (mmHG) from baseline to 4- and 12-months | Both systolic and diastolic blood pressure will be assessed using electronic sphygmomanometer following 5-min rest | Assessed at baseline, 4-months, 12-months |
Change in tumor necrosis factor-alpha (TNF-α) from baseline to 4- and 12-months | Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. | Assessed at baseline, 4-months, 12-months |
Change in interleukin 6 (IL-6) from baseline to 4- and 12-months | Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. | Assessed at baseline, 4-months, 12-months |
Change in interleukin 10 (IL-10) from baseline to 4- and 12-months | Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. | Assessed at baseline, 4-months, 12-months |
Change in interleukin 15 (IL-15) from baseline to 4- and 12-months | Measured in serum using a commercial multiplex immunoassay platform; blood will be drawn after a 10 hour fast. | Assessed at baseline, 4-months, 12-months |
Change in fasting blood glucose glucose from baseline to 4- and 12-months | Plasma glucose assessed after a 10 hour fasting blood draw. Measured using an automated chemistry analyzer. | Assessed at baseline, 4-months, 12-months |
Change in serum insulin from baseline to 4- and 12-months | Serum insulin collected after a 10 hour fasting blood draw. | Assessed at baseline, 4-months, 12-months |
Change in serum lipids (mg/DL) from baseline to 4- and 12-months | Triglycerides, total cholesterol, LDL-C, and HDL-C will be assessed | Assessed at baseline, 4-months, 12-months |
Change in insulin sensitivity (µIU/mL) from baseline to 4- and 12-months | Assessed by calculating homeostatic model assessment (HOMA) scores as: glucose (mg/dl) x insulin (μU/ml)/405. | Assessed at baseline, 4-months, 12-months |
Change in exercise self-efficacy from baseline to 4- and 12-months | Assessed by the 12-item Exercise Self-Efficacy survey (Sallis et al.1987). The range of possible scores for this measure is 1-5, with higher scores indicating higher levels of physical activity self-efficacy. | Assessed at baseline, 4-months, 12-months |
Change in self-regulation for physical activity from baseline to 4- and 12-months | Assessed by the 10- item Self-Regulation Scale from the Health Beliefs Survey (Anderson-Bill 2006). This scale assesses the use of behavioral strategies to incorporate physical activity into daily activities (i.e., take stairs instead of elevator, walking instead of driving when running errands). The range of possible scores for this measure is 1-5, with higher scores indicating higher levels of physical activity self-regulation. | Assessed at baseline, 4-months, 12-months |
Change in social support for physical activity from baseline to 4- and 12-months | Assessed by the Social Support for Exercise survey developed by Sallis et al (1987). This scale assesses social support from family support (10-items, with a possible range of scores from 10-50) and friends (8-items, with a possible score range from from 8-40). Higher scores indicate greater levels of social support. | Assessed at baseline, 4-months, 12-months |
Change in outcome expectations for physical activity from baseline to 4- and 12-months | Assessed using the 9-item Outcome Expectation Scale for Exercise scale, developed by Resnick (2000). The range of possible scores for this measure is 1-5, with higher scores indicating more positive expectancies associated with physical activity engagement. | Assessed at baseline, 4-months, 12-months |
Change in behavioral capability for physical activity from baseline to 4- and 12-months | Assessed using a 6-item scale developed by the research team in previous research. The range of possible scores for this measure is 1-6, with higher scores indicating higher levels of behavioral capability of physical activity. | Assessed at baseline, 4-months, 12-months |
Criteri di eleggibilità
Età idonea
Adulto, Adulto anziano
Età minima
24 Years
Sessi idonei
Donna
Accetta volontari sani
Sì
- Self-reported African American/Black female
- Aged of 24-65 years
- Insufficiently Active (< 60 minutes of moderate-to-vigorous physical activity per week as measured by Exercise Vital Sign Questionnaire)
- BMI > 30 kg/m2
- English speaking and reading
- Ownership of a smartphone with the ability to download applications (i.e., apps)
- Ownership of a smartphone with the ability to receive text messages
- Willingness to receive a physical activity intervention delivered through their smartphone
- Willingness to include their first name or create an alias to be used on their profile page on the Smart Walk app
- Plans to relocate out of Phoenix area in next 12 months
- Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a doctor's note for study participation in provided
- Resting systolic blood pressure greater than 180 mmHG and/or a diastolic blood pressure greater than 120 mmHG , as assessed at baseline or at any other study assessment
- Self-reported participation in another diet or weight loss study at screening
- Pregnant or planning to become pregnant in the next 12 months
Università statale dell'Arizona83 studi clinici attivi da esplorareIstituto nazionale del cuore, dei polmoni e del sangue, Estados Unidos758 studi clinici attivi da esplorareContatti principali dello studio
Contatto: Rodney P Joseph, PhD, 602-496-0772, [email protected]
1 Centri dello studio in 1 paesi
Arizona
Arizona State University, Phoenix, Arizona, 85004, United States
Carina Platte, PhD, Contatto, 602-543-2213, [email protected]
Rodney Joseph, PhD, Investigatore principale
In arruolamento